Characterization of QuantiFERON-TB-Plus Results in Patients with Tuberculosis Infection and Multiple Sclerosis.

ABSTRACT: Disease-modifying drugs (DMDs) for multiple sclerosis (MS) slightly increase the risk of tuberculosis (TB) disease. The QuantiFERON-TB-Plus (QFT-Plus) test is approved for TB infection (TBI) screening. Currently, there are no data available regarding the characterization of QFT-Plus response in patients with MS. This study aimed to compare the magnitude of QFT-Plus responses between patients with MS and TBI (MS-TBI) and TBI subjects without MS (NON-MS-TBI). Additionally, discordant responses to TB1/TB2 stimulation were documented. Results were evaluated considering demographic and clinical data, particularly the impact of DMDs and the type of TB exposure. Patients with MS (N = 810) were screened for TBI (2018-2023). Thirty (3.7%) had an MS-TBI diagnosis, and 20 were recruited for the study

SUBMITTER: Petruccioli E 

PROVIDER: S-EPMC12389123 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature